Viatris Earnings Reports

Viatris posted flat revenue in Q3 2025, with a net loss of $128 million primarily due to a decline in the fair value of Biocon Biologics shares and higher tax expense. Despite this, the company maintained strong adjusted profitability and raised full-year guidance.

Viatris delivered a strong second quarter in 2025, with total revenues exceeding expectations, reflecting the strength and resilience of its diversified global business. The company reported a significant improvement in U.S. GAAP net loss and diluted EPS compared to the prior year, while also reaffirming its full-year 2025 financial guidance ranges across all metrics.

Viatris delivered total revenues in line with expectations, demonstrating strength in its base business. The company made significant pipeline progress with three positive Phase 3 data readouts and returned more than $450 million in capital to shareholders year-to-date, reaffirming its 2025 capital allocation priorities. Despite a U.S. GAAP net loss driven by a goodwill impairment charge, adjusted net earnings and adjusted EBITDA were positive.

Viatris posted Q4 2024 revenue of $3.52 billion, reflecting an 8% decline year-over-year. The company reported a GAAP net loss of $516.5 million and adjusted EPS of $0.54. While the Greater China segment showed positive growth, other geographic regions and product categories experienced declines.

Viatris reported strong Q3 2024 results with total revenues of $3.8 billion, including $133 million from new products. The company repaid approximately $1.9 billion in debt and expanded its innovative portfolio through an exclusive licensing agreement for sotagliflozin. Adjusted EBITDA grew by ~4% to $1.3 billion on a divestiture-adjusted basis, and adjusted EPS grew by ~6% to $0.75 per share on a divestiture-adjusted basis. The company reaffirms its 2024 full-year outlook, expecting revenue growth of ~2% on a divestiture-adjusted operational basis.